scholarly journals Genetic Variants of C-5312TRENIncreased Renin Levels and Diastolic Blood Pressure Response to Angiotensin Receptor Blockers

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Mohammad Saifur Rohman ◽  
Ika Arum Dewi Satiti ◽  
Nashi Widodo ◽  
Mifetika Lukitasari ◽  
Hidayat Sujuti
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Diastolic Pressure ◽  
Blood Pressure Response ◽  
Angiotensin Receptor Blockers ◽  
Pressure Response ◽  
Angiotensin Receptor ◽  
Hypertensive Patients ◽  
Renin Level ◽  
Receptor Blockers

Renin catalyzes the cleavage of angiotensinogen into angiotensin I. Genetic variant C-5312T of renin enhancer has been reported to increase in vitro renin gene transcription. However, no obvious in vivo study was performed to see the renin level in C-5312T when treated with angiotensin receptor blockers (ARB). Therefore, this study aimed to investigate the serum renin level and blood pressure response in ARB treated hypertensive patients. Single nucleotide polymorphism (SNP) of C-5312T was identified in 55 hypertensive patients by using multiplex PCR and renin serum level was assayed by ELISA. The data showed that the increase of serum renin levels after 5 months of ARB treatment was significantly higher in patients with CT/TT genotype (10 pg/mL) than those with CC genotype (4.08 pg/mL) (P= 0.025). Hypertensive patients with CT/TT genotypes also showed less diastolic pressure reduction than CC genotypes in hypertensive patients with valsartan treatment (P= 0.04) or telmisartan treatment (P= 0.03). Finally, these findings suggested that SNP of C-5312TRENenhancer might contribute to higher increased renin serum levels and less diastolic blood pressure response to ARB treatment.

scholarly journals Antihypertensive drug prescription trends in Shahrekord, Iran

2021 ◽  
Vol 11 (1) ◽  
pp. e13-e13
Author(s):  
Ahmadreza Maghsoudi ◽  
Maryam Dehghani Mobarakeh ◽  
Ali Momeni ◽  
Alireza Nematollahi ◽  
Shahin Asgari ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Drug Prescription ◽  
Angiotensin Receptor ◽  
Cross Sectional ◽  
Hypertensive Patients ◽  
The Status ◽  
Receptor Blockers

Introduction: Hypertension is one of the most leading causes of death worldwide. It is an important risk factor for ischemic heart disease (IHD), chronic kidney disease (CKD) and cerebrovascular diseases. Objectives: The aim of the study was evaluation of the status of blood pressure control and trends in prescribed antihypertensive medication usage among hypertensive patients in Shahrekord, Iran. Patients and Methods: In a cross-sectional descriptive study 250 hypertensive patients were enrolled. The patients were evaluated based on the status of blood pressure (BP) control and the prescription trends and efficacy of antihypertensive drugs. The data were also evaluated in subgroups of diabetics or non-diabetics, smokers or non-smokers, patients with or without CKD, patients with or without IHD. Results: A total of 250 patients (149 women and 101 men) were enrolled in this study. The mean age of participants was 66.22±13.58 years. Mean systolic and diastolic BP were 143.4±29.4 mm Hg and 85.8±12.5 mm Hg respectively. Poor controlled BP was seen in 106 patients. The more common prescribed antihypertensive drugs were angiotensin receptor blockers (46%), diuretics (33.6%) and beta-blockers (32.8%). Conclusion: The study showed that most of the patients had poor controlled BP and physicians increasingly prescribe angiotensin receptor blockers.

scholarly journals Study of utilization pattern and analysis of efficacy of newer angiotensin receptor blockers in patients with hypertension and type-II diabetes with or without hypertension

2017 ◽  
Vol 5 (7) ◽  
pp. 2931
Author(s):  
Rajashree Samal ◽  
Jyoti Prakash Panda ◽  
Kali Prasad Pattnaik
Keyword(s):  
Blood Pressure ◽  
Type Ii Diabetes ◽  
Urinary Albumin Excretion ◽  
Angiotensin Receptor Blockers ◽  
Urinary Albumin ◽  
Type Ii ◽  
Angiotensin Receptor ◽  
Utilization Pattern ◽  
Hypertensive Patients ◽  
Receptor Blockers

Background: Interventions that target blood pressure control and proteinuria, specifically interruption of the Renin-angiotensin-aldosterone system (RAAS), have been utilized in attenuating cardiovascular complications. Angiotensin receptor blockers (ARBs) have been reported to have certain advantages. The objective of the study was to evaluate and compare the utilization pattern and efficacy of different ARBs in patients with HTN and associated type-II diabetes.Methods: Hypertensive patients with or without type-II diabetes treated with ARB based regimen were selected.  The BP and 24 hours urinary albumin excretion were analysed at baseline and after three months of treatment.Results: Mean reduction in systolic blood pressure(SBP) was more with ARBs and calcium channel blocker(CCB) combination. Telmisartan alone and with ACEI reduced diastolic blood pressure (DBP) maximally in diabetic hypertensive patients. Proteinuria was significantly reduced with telmisartan (p<0.001) and olmesartan (p<0.05) based therapy. The side effects were minimal with ARB based therapy. Telmisartan was the costliest among all ARBsConclusions: There was suboptimal use of combination therapy in diabetic hypertensive patients.  Telmisartan was having the better control on 24hr urinary albumin excretion.

Sign in / Sign up

Export Citation Format

Share Document